Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.

MLA

Pasvolsky, Oren, et al. “Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.” Transplantation and Cellular Therapy, vol. 28, no. 11, Nov. 2022, p. 752.e1-752.e6. EBSCOhost, https://doi.org/10.1016/j.jtct.2022.07.028.

APA

Pasvolsky, O., Milton, D. R., Rauf, M., Tanner, M. R., Bashir, Q., Srour, S., Tang, G., Saini, N., Ramdial, J., Masood, A., Nieto, Y., Lee, H. C., Patel, K. K., Kebriaei, P., Thomas, S. K., Weber, D. M., Orlowski, R. Z., Shpall, E. J., Champlin, R. E., & Qazilbash, M. H. (2022). Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy, 28(11), 752.e1-752.e6. https://doi.org/10.1016/j.jtct.2022.07.028

Chicago

Pasvolsky, Oren, Denái R Milton, Mikael Rauf, Mark R Tanner, Qaiser Bashir, Samer Srour, Guilin Tang, et al. 2022. “Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.” Transplantation and Cellular Therapy 28 (11): 752.e1-752.e6. doi:10.1016/j.jtct.2022.07.028.